News | February 06, 2007

DES Trial to Study Complexities of CVD in Women

Feb. 7, 2007 — Abbott has announced its plan to launch the world's first drug-eluting stent clinical trial solely in women. Performance of the Xience V Everolimus Eluting Coronary Stent System will be the focus of the SPIRIT WOMEN trial, designed specifically to study CVD in women and how it differs from men. Xience V is not FDA cleared for commercial sale in the U.S.

Approximately 2,000 women from 100 sites throughout Europe, Asia-Pacific, Canada and Latin America will be included in the trial, which will evaluate patient and disease characteristics specific to women as well as treatment outcomes such as rate of death, heart attack and target vessel revascularization (TVR) and potential risk of stent thrombosis. The trial will yield specific data on CVD and how it is diagnosed in women.

According to the National Center on Health Statistics, more women than men die of cardiovascular disease every year, yet women receive only 33 percent of angioplasties, stents and bypass surgeries; 28 percent of implantable defibrillators; and 36 percent of open-heart surgeries. This may be partially explained by the greater diagnosis challenges in women, who exhibit different, and often more gradual and subtle symptoms such as shortness of breath, dizziness, nausea, indigestion, vomiting, unexplained fatigue and back, shoulder blade or jaw pain.

"The SPIRIT WOMEN trial will contribute to therapy access by increasing awareness and understanding of CVD in women while further evaluating the performance of our XIENCE V drug-eluting stent in this patient population," said John M. Capek, Ph.D., president, Abbott Vascular. "As a leader in vascular care, Abbott believes that it is our role not only to provide the best technologies, but also to ensure that they are being used effectively in as broad a patient population as possible."

Pending requisite approvals from regulatory bodies and clinical trial sites, patient enrollment may begin by mid-2007.

For more details visit www.abbott.com .

Related Content

Titanium-Nitride-Oxide Stent Superior to Bioabsorbable DES in Acute Coronary Syndrome Patients

Image courtesy of Hexacath

News | Stents Drug Eluting | May 31, 2018
Late-breaking trial results presented at the EuroPCR Congress, May 21-24 in Paris, France, found the Optimax titanium-...
Orsiro DES Shows Lowest Two-Year Target Lesion Failure in BIO-RESORT Trial
News | Stents Drug Eluting | May 31, 2018
Two-year outcome data from the BIO-RESORT randomized controlled trial were presented in a late-breaking clinical trials...
OCT Reveals Excellent Healing Profile for Complex CAD Patients With Resolute Onyx DES
News | Stents Drug Eluting | May 29, 2018
Investigators recently unveiled clinical data from the independently run Onyx 1-Month OCT Study showing strong early...
Abbott's Xience Sierra Stent Receives FDA Approval
Technology | Stents Drug Eluting | May 25, 2018
Abbott announced it received approval from the U.S. Food and Drug Administration (FDA) for Xience Sierra, the newest...
Medtronic Launches 2 mm Onyx DES
Technology | Stents Drug Eluting | February 26, 2018
February 26, 2018 – Designed specifically for small vessels, Medtronic plc announced U.S.
Detroit Medical Center Heart Hospital Uses Michigan's First EluNIR Drug-Eluting Stent
News | Stents Drug Eluting | February 19, 2018
February 19, 2018 — The Detroit Medical Center’s (DMC) interventional cardiology team at Heart Hospital recently beca
Biotronik Symposium Highlights Differing Roles of Drug-Eluting Stents and Magnesium Scaffolds in Clinical Practice
News | Stents Drug Eluting | January 25, 2018
January 25, 2018 – Data presented at the Biotronik-sponsored...
The Abbott Absorb Bioresorbable Vascular Scaffold (BVS) bioabsorbable stent.

The Abbott Absorb Bioresorbable Vascular Scaffold (BVS).

Feature | Stents Drug Eluting | January 17, 2018 | Dave Fornell
There was no shortage of interest in bioresorbable stent technologies at the many sessions offered on this topic or b
Cordis and Medinol Announce FDA Approval of EluNIR Drug-Eluting Stent System
Technology | Stents Drug Eluting | December 13, 2017
Cordis, a Cardinal Health company, and Medinol recently announced U.S. Food and Drug Administration (FDA) approval of...
The Xience Sierra stent.
Technology | Stents Drug Eluting | November 09, 2017
November 9, 2017 — Abbott received European CE mark for Xience Sierra, the newest generation of the company's Xience
Overlay Init